Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

55.21
+0.63001.15%
Pre-market: 55.800.5900+1.07%09:23 EST
Volume:2.12M
Turnover:115.48M
Market Cap:5.26B
PE:-9.89
High:56.15
Open:54.18
Low:52.82
Close:54.58
52wk High:78.48
52wk Low:30.04
Shares:95.30M
Float Shares:90.53M
Volume Ratio:0.79
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5830
EPS(LYR):-4.3416
ROE:-25.34%
ROA:-13.05%
PB:3.07
PE(LYR):-12.72

Loading ...

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news
·
Yesterday

RBC Raises Price Target on CRISPR Therapeutics to $50 From $42, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Yesterday

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Yesterday

Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress

TIPRANKS
·
Yesterday

Merck's Heart Pill Slashes Cholesterol Levels in Test Patients -- Barrons.com

Dow Jones
·
Yesterday

Crispr Therapeutics price target lowered to $50 from $52 at Clear Street

TIPRANKS
·
Yesterday

Crispr Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Yesterday

Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)

TIPRANKS
·
Nov 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 10

CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

Benzinga
·
Nov 10

Earnings Flash (CRSP) CRISPR Therapeutics Posts Q3 Net Loss $1.17 a Share, vs. FactSet Est of $1.25 Loss

MT Newswires Live
·
Nov 10

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 10

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

TIPRANKS
·
Nov 10

Promising Phase I Results of CTX310 Justify Buy Rating for CRISPR Therapeutics

TIPRANKS
·
Nov 10

Promising Efficacy of Crispr Therapeutics’ CTX310 in Dyslipidemia Treatment Drives Buy Rating

TIPRANKS
·
Nov 10

Crispr Therapeutics announces Phase 1 data for CTX310

TIPRANKS
·
Nov 10

More Drugs to Fight High Cholesterol Are Emerging -- WSJ

Dow Jones
·
Nov 09

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

GlobeNewswire
·
Nov 09

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

GlobeNewswire
·
Nov 08

Wedbush Adjusts CRISPR Therapeutics Price Target to $9 From $13, Maintains Outperform Rating

MT Newswires Live
·
Nov 05